United States · Markets & Finance · Morningstar

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Published by Morningstar · United States 16 h ago

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss In the MEERKAT and SANDCAT studies, vamikibart…

Read the full article on Morningstar Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

TechCrunch

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Share

Also worth reading

Microsoft’s Satya Nadella says AI models need an ‘emergency brake’

Satya Nadella says a company's relationship with AI should have trust issues

Pemex Needs Nearly $110 Billion to Hit Mexico's Output Targets

Microsoft's Nadella says AI needs an ‘emergency brake’ that humans control

SA Asks: Is now the time to buy quantum stocks? If so, which ones?

Ship captains and crews transiting the Strait of Hormuz make so much danger pay that they’re ‘almost being viewed as mercenaries’